J Korean Diabetes > Volume 16(4); 2015 > Article
The Journal of Korean Diabetes 2015;16(4):269-275.
DOI: https://doi.org/10.4093/jkd.2015.16.4.269    Published online December 24, 2015.
이상지질혈증 치료 약제의 최신지견
Update on the Pharmacologic Agents for Dyslipidemia.
Sang Hak Lee
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. shl1106@yuhs.ac
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
Key Words: Cholesterol ester transfer proteins, Ezetimibe, Fibric acids, Human PCSK9 protein, Hydroxymethylglutaryl-CoA reductase inhibitors, Niacin, Omega-3 fatty acids
METRICS Graph View
  • 1 Crossref
  •  0 Scopus
  • 1,471 View
  • 9 Download
Related articles

Pharmacologic Prevention of Prediabetes2009 December;10(4)

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer